News Headlines Article

Five Prime, Adimab ink deal around potential cancer treatments
San Francisco Chronicle

Five Prime Therapeutics Inc. closed its second collaboration since it went public in September, bagging a deal around antibodies that could stimulate the immune system to attack cancer cells. Terms of the deal with Adimab LLC were not disclosed Thursday, but Adimab will use its antibody discovery technology to identify fully human antibodies for South San Francisco-based Five Prime.